CEMIP2

Across TCGA pan-cancer cohorts, CEMIP2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CEMIP2 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CEMIP2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CEMIP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, ACC, and BLCA are the cancer types where CEMIP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.906	0.424	.005	30	view →
ACC	OS	Median	All	0.273	0.802	.017	15	view →
BLCA	OS	Median	IV	0.018	0.600	<.001	12	view →
PRAD	DFS	Median	All	0.168	0.886	<.001	6	view →
READ	DFS	Median	II,III,IV	0.112	0.800	.002	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CEMIP2–UCEC (DFS)

Open the UCEC breakdown →